Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
1(20%)
Results Posted
100%(2 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_1
2
40%
Ph not_applicable
2
40%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
N/ANon-phased studies
2(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Recruiting1
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
66.7%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (50.0%)
N/A2 (50.0%)

Trials by Status

completed240%
recruiting120%
withdrawn120%
terminated120%

Recent Activity

1 active trials
Showing 5 of 5
withdrawnnot_applicable

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

NCT01314508
recruiting

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

NCT00903110
completedphase_1

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

NCT02636270
terminatedphase_1

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

NCT00490100
completednot_applicable

IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

NCT01588093

Clinical Trials (5)

Showing 5 of 5 trials
NCT01314508Not Applicable

Increlex Treatment of Children With Chronic Liver Disease and Short Stature

Withdrawn
NCT00903110

Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Recruiting
NCT02636270Phase 1

IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency

Completed
NCT00490100Phase 1

Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1

Terminated
NCT01588093Not Applicable

IGF-I Induced Muscle Glucose Uptake and Interstitial IGF-I Concentrations

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5